AIM ImmunoTech CEO to Present at H.C. Wainwright Global Investment Conference. Innovation in Cancer and Viral Disease Therapeutics
AIM ImmunoTech Inc., a leading immuno-pharma company, has made an exciting announcement regarding its participation at the H.C. Wainwright 25th Annual Global Investment Conference. The company’s CEO, Thomas K. Equels, will be presenting at the event, which will be held from September 11th to September 13th, 2023, in New York, NY, both in-person and virtually.
In addition to the presentation, AIM ImmunoTech’s management will also be available for virtual one-on-one meetings with registered members of the investor community. This offers a unique opportunity for interested individuals to engage directly with the company’s key figures and gain valuable insights into its innovative approach to cancer and viral disease therapeutics.
AIM ImmunoTech’s presentation will be available for on-demand viewing via a video webcast starting from Monday, September 11th, at 7:00 AM ET. Registered attendees will be able to access the webcast on the Events page in the Investors section of the company’s website (aimimmuno.com). Furthermore, the webcast replay will be archived for a period of 90 days following the event.
The H.C. Wainwright Global Investment Conference provides a platform for AIM ImmunoTech to showcase its cutting-edge research and development efforts focused on therapeutics for various types of cancers, immune disorders, and viral diseases, including the ongoing battle against COVID-19. The company’s lead product, Ampligen® (rintatolimod), is an investigational drug that has shown great promise as a first-in-class immuno-modulator with broad spectrum activity. Ampligen® is a dsRNA and highly selective TLR3 agonist that is currently being evaluated in clinical trials targeting globally important cancers, viral diseases, and immune system disorders.
AIM ImmunoTech’s commitment to advancing novel treatments and therapies sets it apart as a key player in the field of immuno-pharmaceuticals. With its participation in the H.C. Wainwright Global Investment Conference, the company aims to garner increased interest and support from the investment community. By engaging with investors and sharing updates on its groundbreaking research, AIM ImmunoTech stands poised to make significant contributions in the fight against cancer, viral diseases, and immune disorders.
